Rosuvastatin for enhancement of aneurysm neck endothelialization after coil embolization: promotion of endothelial progenitor cells in a rodent model

Peixi Liu, MD,1 Qingzhu An, MD, PhD,1 Xi Chen, MD,1 Jun Huang, MD,3 Guo-Yuan Yang, MD, PhD,2,3 and Wei Zhu, MD, PhD1

1Department of Neurosurgery, Huashan Hospital of Fudan University; 2Department of Neurology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine; and 3Neuroscience and Neuroengineering Research Center, Med-X Research Institute and School of Biomedical Engineering, Shanghai Jiao Tong University, Shanghai, China

OBJECTIVE Coil embolization is a safe, efficient, and minimally invasive technique for the treatment of intracranial aneurysms. However, coil embolization is associated with a higher risk of recurrence than clip ligation. In this study, the authors explore a new approach through the promotion of endothelial progenitor cells (EPCs) to optimize endothelialization of the aneurysm neck and reduce the risk of recurrence.

METHODS A coiled aneurysm model was created in 48 adult male Sprague-Dawley rats via microsurgery. Half of these animals were treated with rosuvastatin (20 mg/kg) in saline via gavage for 10, 20, or 30 days. The other half were administered saline without rosuvastatin. An additional 15 rats underwent "mock surgery" (identical anesthesia and saline gavage but no surgery). The endothelial repair process in the coiled aneurysms was evaluated via flow cytometry, immunostaining, and electronic microscopy. The mock surgery group was used for comparison in flow cytometry studies. The effects of rosuvastatin on viability and functioning of Sprague-Dawley rat bone marrow–derived EPCs were also explored via MTT, migration, and tube formation assays.

RESULTS The aneurysm neck repair score was significantly higher in the rosuvastatin-treated rats than in the untreated rats (p < 0.05). The circulating EPC count was increased and maintained at a higher level in rosuvastatin-treated rats compared with the aneurysm rats that did not receive rosuvastatin (p < 0.05). Immunostaining showed that the aneurysm neck endothelium was more integrated and the number of kinase insert domain receptor–positive cells was increased in the rosuvastatin-treated rats. Further study demonstrated that rosuvastatin promoted EPC proliferation, migration, and tube formation.

CONCLUSIONS Rosuvastatin promoted endothelialization of the coiled aneurysm neck via induction of EPCs, suggesting that promoting endothelialization provides an additional therapeutic opportunity during vascular endothelium repair.

http://thejns.org/doi/abs/10.3171/2015.3.JNS142841

KEY WORDS aneurysm; endothelial progenitor cells; endothelialization; rosuvastatin; vascular disorders

In the treatment of intracranial aneurysms, coil embolization is safer, quicker, more efficient, and less invasive than clip ligation. Incomplete endothelialization of the aneurysm neck after coil placement, however, is associated with an increased risk of aneurysm recurrence and even rupture. Improving endothelialization of the aneurysm neck may therefore improve the long-term outcome for patients treated with coil embolization.

Endothelial progenitor cells (EPCs) were initially identified from human peripheral blood and were found to express CD34 and kinase insert domain receptor (KDR).2 Sources of EPCs include adult bone marrow, peripheral blood, umbilical cord blood, and tissue resident cells.4 EPCs can exist for a relatively long period within the circulating blood, serving to maintain vascular homeostasis and being involved in vascular repair. Circulating EPCs

ABBREVIATIONS DMSO = dimethylsulfoxide; EPC = endothelial progenitor cell; GDC = Guglielmi detachable coil; H & E = hematoxylin and eosin; KDR = kinase insert domain receptor; MTT = 3-(4,5-dimethylthiazolyl-2)-2,5-diphenyltetrazolium bromide; OD = optical density; SEM = scanning electron microscope; vWF = von Willebrand factor.


INCLUDE WHEN CITING Published online September 25, 2015, DOI: 10.3171/2015.3.JNS142841.
are an interesting area for research because of their clinical application potential, and they are an independent risk marker for future cardiovascular events. Studies involving animal models and human clinical studies have indicated that EPC transplantation can improve the functional recovery of the heart and limbs after ischemic injury.

Experimental studies of aneurysms have shown that the endovascular injection of EPCs can improve aneurysm neck neointima formation in a rabbit aneurysm model. In addition, we have previously shown that bone marrow–derived EPCs play a crucial role in the closure and reconstruction of the aneurysm neck after coil embolization. EPCs have demonstrated a robust effect on aneurysm neck endothelialization and the prevention of recurrence. Because EPCs are involved in the vascular repair and remodeling process, EPC-mediated therapy has been proposed as a potential treatment for vascular disease. Clinical studies have also shown that specific vascular diseases are correlated with EPC deficiencies and dysfunctions. Increasing the local level of EPCs may therefore provide a new opportunity for aneurysm neck endothelialization.

Statins are a class of drugs that are used to lower cholesterol levels by inhibiting the enzyme HMG-CoA (3-hydroxy-3-methylglutaryl-coenzyme A) reductase. Rosuvastatin is a statin family member that is used to treat high cholesterol levels and related conditions and prevent cardiovascular disease. Previous studies have shown that statins affect several processes involved in vascular repair and remodeling, including angiogenic and angiostatic responses. It is largely unknown, however, whether statins stimulate angiogenesis and vasculogenesis through the promotion of EPC function.

Because of the importance of endothelialization in aneurysm treatment, we explored the effect of rosuvastatin on EPC mobilization and activity in the treatment of intracranial aneurysms.

### Methods

#### Experimental Protocol and Rat Coiled Aneurysm Model

The animal protocol used in this study was approved by the institutional animal care and use committee of Fudan University, and the experimental protocol was reviewed and approved by the university’s ethics committee. Sixty-three adult male Sprague-Dawley rats (Shanghai Slac Laboratory Animal Co. Ltd.) weighing 200 to 250 g were randomly divided into 3 groups for the in vivo portion of this study as follows. 1) Animals in the “aneurysm rat treated with rosuvastatin” group (AN-Rosu group, n = 24) were anesthetized with isoflurane using a vaporizer (Matrix, Midmark). The model was established using surgical microscopy (Leica Microsystems), and vasculoplasty was performed on the rats to induce arterial artery aneurysms as previously described. A vessel segment was obtained from a healthy rat abdominal aorta and used as a donor segment. The anastomosed aneurysm developed in the abdominal aorta, between the renal vein and iliolumbar vein. The proximal area of the aneurysm was constricted by partial ligation to create an aneurysm neck, and the distal region of the anastomosing vessel segment was completely ligated. A coiled aneurysm model was created via Guglielmi detachable coil (GDC) elaboration prior to distal ligation. The AN-Rosu group was treated with 20 mg/kg rosuvastatin suspension saline liquid via gavage each day for 10, 20, or 30 days. 2) Animals in the “aneurysm rat treated without rosuvastatin” group (AN group, n = 24) also underwent microsurgery as above; the aneurysms were coiled as in the AN-Rosu group, and the animals were treated with an equal amount of saline by gavage each day, but they did not receive any rosuvastatin. 3) Animals in the mock-surgery group (MS group, n = 15) received inhalation anesthesia with isoflurane like the aneurysm groups but were not subjected to any actual surgery. These animals were subsequently administered saline via gavage each day (as in the AN group) (Fig. 1).

A 3-T MRI system (Magnetom Verio, Siemens Healthcare) was used for 3D MR angiography to detect aneurysm formation and coiled condition at 3 days after model establishment in the AN-Rosu and AN groups.

#### Pathological Assessment

Thirty days after the anastomosis procedure, the coil-embolized aneurysms obtained from 6 rats in each group were resected under inhalation anesthesia and fixed in 4% formalin solution. After resection of the aneurysm and while still anesthetized, the rats were killed by means of cervical dislocation. After the sample was embedded in paraffin, a low-speed saw (SYJ-150 Kejing Automation Equipment Co.) was used to section the distal part of the coil aneurysm as previously described. Coil fragments were removed carefully under microscopy, and the sections were re-embedded in paraffin. Then, the vascular tissue was sectioned again into 5-μm-thick slices using a microtome (Model RM2165, Leica Microsystems). The sections were floated in a water bath (42°C), mounted on Superfrost Plus slides (Fisher Scientific International), and dried overnight in an oven at 37°C (Fig. 2A). Three sections were randomly chosen for hematoxylin and eosin (H & E) staining. For immunohistochemical analysis, anti–KDR (Abcam), antivon Willebrand factor (vWF) (Abcam), and anticalcium smooth muscle actin (αSMA) (Abcam) were used as primary antibodies and 3,3′-diaminobenzidine (DAB) plus chromogen (Thermo Fisher Scientific) was used for substrate visualization, according to the manufacturers’ protocol.

After H & E staining, the morphological changes in the neck of the experimental aneurysm (proximal to the parent artery) were assessed. Based on the morphological characteristics, we established an aneurysm repair score consisting of aneurysm neck integrity and luminal endothelial layer continuity. For the integrity assessment, a value of 3 indicated a complete occlusion and a flat aneurysm neck, a value of 2 indicated a complete occlusion and small “dog ears,” a value of 1 indicated a complete occlusion and large “dog ears,” and a value of 0 indicated re-canalization. With respect to endothelial layer continuity, a value of 3 indicated complete endothelial continuity, a value of 2 indicated obvious but small defects, a value of 1 indicated large defects, and a value of 0 indicated no endothelium formation (Table 1, Fig. 2B). We randomly chose 3 sections from each sample and the score of each sample was the mean of the 3. During assessment, the researcher estimator was blinded.
A scanning electron microscope (SEM, Hitachi SU8000) was used to evaluate the endothelialization of the aneurysm neck. After 30 days of gavage, the aneurysm area on the abdominal artery was removed from 3 animals in each of the 2 aneurysm groups, and the exposed luminal surface of the aneurysm neck was cut off from the parent artery along a longitudinal line. (The procedure was performed under inhalation anesthesia, and the animals were killed by cervical dislocation afterward.) The 6 vessel segments were fixed in 2.5% glutaraldehyde and processed for en face SEM imaging. The morphological membrane coverage of the orifice of the aneurysm neck and the endothelial cells adhering to the aneurysm neck were detected using a cold field emission SEM. The endothelial cells were identified as sheets of closely connected monolayer cells with a spindle or polygonal shape.

Flow Cytometry

CD34+/KDR+ cells were defined as EPCs. At Day 10, 20, or 30 after aneurysm formation, the circulating blood was drained from 5 rats in each group via the carotid artery. (The rats were subsequently killed by cervical dislocation under anesthesia.) The rat blood was immediately stored at 4°C. The mononuclear cells were then isolated via Ficoll (Histopaque-1077, Sigma) density gradient centrifugation within 4 hours after blood collection. The CD34 and KDR antibodies were added into the mononuclear suspension and incubated for 1 hour. After washing, the cells were labeled using Alexa Fluor 546 donkey anti–sheep IgG (Invitrogen) and Alexa Fluor 488 donkey anti–rabbit IgG (Invitrogen). After 30 minutes of incubation, the cells were washed and then analyzed using a flow cytometer (FACSARia II, Becton Dickinson) by collecting 300,000 events. The data were analyzed using FACS Diva Software. Gates were set on the forward- and side-scatter (FSC/SSC) plot corresponding to select mononuclear cells and the results were expressed as a percentage of the mononuclear cell events.

EPC Isolation, Culture, and Identification

An additional 30 adult male Sprague-Dawley rats weighing 200 to 250 g were used for the in vitro portion of this study. Under inhalation anesthesia, the animals’ femurs were removed, and the animals were then killed by cervical dislocation. Bone marrow cells were isolated from rat femur marrow via Ficoll density gradient centrifugation and then cultured on fibronectin-coated dishes with EGM-2 (Lonza) medium at 37°C in a 5% CO₂ incubator. The attached cells were used for DiI-AcLDL (Invitrogen) and FITC-UEA-I (Sigma) staining. The adherent primary cells were incubated with 15 μg/mL DiI-AcLDL for 4 hours at 37°C. The cells were fixed with 10% paraformaldehyde for 10 minutes and counterstained with FITC-UEA-I. For flow cytometry analysis, adherent primary cells (10th day) were resuspended, and KDR and CD34 antibodies were added to the mononuclear suspension, which was then incubated for 1 hour. After the cells were washed, they were labeled with Alexa Fluor 546 donkey anti–sheep IgG and Alexa Fluor 488 donkey anti–rabbit IgG. The cells were washed and analyzed using a FACSDiva II flow cytometer by collecting 10,000 events. The data were analyzed using FACSDiva software.

Cell Proliferation, Migration, and Tube Formation Assay

Rosuvastatin calcium was dissolved in dimethylsulfoxide (DMSO, Sinopharm Chemical Reagent Co.) and filter sterilized. The rosvastatin solution was diluted in the EGM-2 culture medium to different concentrations based on the experimental requirements. EPCs were transferred to 96-well plates at a cell density and the endothelial cells adhering to the aneurysm neck were detected using a cold field emission SEM. The endothelial cells were identified as sheets of closely connected monolayer cells with a spindle or polygonal shape.
of $5 \times 10^4$ cells per well. After 24 hours, the cell culture medium was replaced with culture medium containing rosuvastatin at one of the following concentrations: 0.001, 0.01, 0.1, 1, 10, and 100 $\mu$mol/L. The cells were incubated for another 24 hours. Then, the culture medium in each well was removed and replaced with 10 $\mu$l yellow tetrazolium MTT (3-[4,5-dimethylthiazolyl-2]-2,5-diphenyltetrazolium bromide) and 90 $\mu$l EGM-2 medium. After 4 hours of incubation, the MTT culture medium in each well was removed and replaced with 100 $\mu$l DMSO. The plates were placed in a rocking incubator for 10 minutes. Finally, the 96-well plates were analyzed using a microplate reader (BioTek) at 490 nm. Changes in the optical density (OD) were used to evaluate the viability of EPCs treated with different concentrations of rosuvastatin.

For the migration assay, the EPCs were placed into 24-well plates and incubated for 48 hours. Then, a pipette tip was used to scratch the cell monolayer across the center of each well. The detached cells were removed via washing, and the remaining adherent EPCs were treated with rosuvastatin (100 $\mu$mol/L) for 24 hours. The cells were then fixed, and propidium iodide (BD Pharmingen) stain-
For the tube formation test, EPCs were pretreated with 100 μmol/L rosuvastatin for 24 hours. The individual wells of a 96-well plate were coated with 30 μl Matrigel basement membrane matrix (BD Biosciences). Next, 3 × 10³ rosuvastatin-treated EPCs were gently added to each gel-coated well. After 20 hours, the cells were dyed with calcein AM and examined via fluorescence microscopy. Images were acquired and analyzed for tube formation using the Wimasis image analysis software program. The total number of nets (distinct regions of tubes that contain at least 1 branching point) was used to estimate the level of tube formation. Isolated tubes were not considered as nets.

Statistical Analysis
The statistical analysis was performed using IBM SPSS Statistics version 19, and graphs were generated in GraphPad Prism version 5.01. Two-way ANOVA tests were used to analyze the percent of circulating EPCs (monocytes) identified by flow cytometry. One-way ANOVA tests were used to analyze the change in the OD value (%) in the MTT assay, the fluorescent area (%) in the migration assay, and the total number of nets in the tube formation assay; p values less than 0.05 were considered statistically significant.

Results
Rat Aneurysm Model
After surgical vascular anastomosis, a rat aneurysm model was created. The surgery was performed in a total of 50 rats, but 2 rats died as a result of anesthetic overdose (the mortality rate was 4%). The aneurysm was filled with circulating blood after surgery, and MR angiography confirmed the success of aneurysm formation in all 48 surviving animals. Finally, MR angiography performed 3 days later confirmed that the aneurysm was completely coiled (Fig. 1).

Histological Findings
H & E staining demonstrated that a more integrated aneurysm neck was formed and more spindle-like slender cells were present in the aneurysm necks of the AN-Rosu rats. In the AN rats, the intima of most of the aneurysm necks showed different degrees of a dog ear shape, and many small areas of cellular hyperplasia were also detected proximal to the aneurysm. The aneurysm repair score was significantly higher in the AN-Rosu group than in the AN group (5.7 ± 0.14 vs 4.4 ± 0.40, p < 0.05, Fig. 3A). Many KDR⁺ cells were detected in the inner surface of the aneurysm neck in the AN-Rosu rats; however, few KDR⁺ cells were detected in the rats of the AN group. Further study demonstrated that there was a vWF⁺ cell layer in the aneurysm neck in both the AN-Rosu group and the AN group rats, suggesting that an endothelial cell layer formed in both groups. However, the vWF layer in the AN-group animals exhibited a lack of continuity (Fig. 3B and C). We also examined the lumen of the aneurysm sac. We found that KDR, vWF, and αSMA expression were increased in the rosuvastatin-treated (AN-Rosu) rats compared with the AN group rats, suggesting that growth in the lumen occurred (Figs. 3D–F).

Scanning Electron Microscopy Examination
Scanning electron microscopy showed the level of endothelialization in the aneurysm neck, and we found better endothelium coverage in the rats in the AN-Rosu group than in the AN group rats; this improvement primarily consisted of simple squamous epithelial cells at the bottom of the aneurysm neck. Overall, the rats that did not receive rosuvastatin demonstrated a similar sealing effect compared with the rosuvastatin-treated rats. However, some of the aneurysms were closed primarily with fibroblasts and smooth muscle cells at the bottom of the aneurysm necks. Endothelial cells were rarely observed in the AN group, and when present, they displayed long, flat, and fusiform morphological characteristics (Fig. 3D).

Flow Cytometry
On the 10th day after aneurysm formation, the number of circulating EPCs was significantly elevated. The number of circulating EPCs in both groups of rats with aneurysms (both treated and untreated) was different from that in the MS group by 10 days of treatment. The circulating EPCs showed no significant difference on the 20th day. On the 30th day, the level of circulating EPCs was mainly elevated by rosuvastatin treatment instead of aneurysm formation, and AN-Rosu rats showed a significant increase in the number of circulating EPCs after 30 days of treatment compared with the other 2 groups (p < 0.05, Table 2, Fig. 3E).

EPC Isolation and Identification
We isolated EPCs from the rat bone marrow and found that many cells showed a round, cobblestone-like morphology in the primary adherent cell culture. Furthermore, the majority of these primary cells showed uptake of Dil-AcLDL and FITC-UEA-I (Fig. 4A), suggesting that these cells were EPCs. In a flow cytometry analysis, we demonstrated that 67% ± 3.2% of the cultured cells were KDR⁺, 49% ± 3.6% were CD34⁺, and 35% ± 1.8% were KDR⁺/CD34⁺. The flow cytometry analysis indicated that these KDR⁺/CD34⁺ cells were EPCs (Fig. 4B).

<table>
<thead>
<tr>
<th>Item</th>
<th>Score</th>
</tr>
</thead>
<tbody>
<tr>
<td>Aneurysm neck integrity</td>
<td></td>
</tr>
<tr>
<td>Complete occlusion &amp; flat aneurysm neck</td>
<td>3</td>
</tr>
<tr>
<td>Complete occlusion &amp; small &quot;dog ears&quot;</td>
<td>2</td>
</tr>
<tr>
<td>Complete occlusion &amp; large &quot;dog ears&quot;</td>
<td>1</td>
</tr>
<tr>
<td>Recanalization</td>
<td>0</td>
</tr>
<tr>
<td>Luminal endothelial layer continuity</td>
<td></td>
</tr>
<tr>
<td>Complete endothelial continuity</td>
<td>3</td>
</tr>
<tr>
<td>Obvious but small defect</td>
<td>2</td>
</tr>
<tr>
<td>Large defect</td>
<td>1</td>
</tr>
<tr>
<td>No endothelium formation</td>
<td>0</td>
</tr>
</tbody>
</table>
Effect of Rosuvastatin on EPC Viability and Functioning

MTT Assays

We showed that the viability of EPCs after 24 hours of rosuvastatin treatment increased in a dose-dependent manner that plateaued at 100 \( \mu \text{mol/L} \). We found that 100 \( \mu \text{mol/L} \) of rosuvastatin treatment for 24 hours induced a marked increase in colony formation compared with the untreated cells. Based on this result, 24-hour treatment with 100 \( \mu \text{mol/L} \) rosuvastatin was selected for the following experiments (Table 3, Fig. 4C).

Migration Assay

Cell monolayers applied to wells with a scratch technique and treated for 24 hours with 100 \( \mu \text{mol/L} \) rosuvastatin showed increased migration compared with the untreated control. These results suggest that rosuvastatin enhances the migratory ability of EPCs, which is critical for their role in artery repair and regeneration.
Rosuvastatin showed greatly increased EPC migration (p < 0.05, Table 4, Fig. 4C).

**Tube Formation Assay**

Similar to the migration assay, we found that 24-hour treatment with 100 μmol/L rosuvastatin also increased EPC tube formation compared with the control (p < 0.05, Table 4, Fig. 4C).

**Discussion**

In the present study, we successfully established a rat coiled aneurysm model via vasotransplantation and used MR angiography to confirm the feasibility of experimental aneurysm embolization. Rosuvastatin treatment was associated with a significant increase in the number of circulating EPCs in the rats with coil-treated aneurysms, and EPCs also participated in aneurysm neck endothelialization. The histological and SEM examinations demonstrated that rosuvastatin produced a robust effect on aneurysm neck closure and endothelialization. The experimental aneurysm repair score assessment system that we used in this study is the first such system to be reported, and the aneurysm repair score reflected the interaction between aneurysm embolization and coverage of endothelial cells, which is essential in preventing aneurysm recurrence. Although there was subjective bias during the assessment, the use of researchers who were blind to the conditions and assessment of multiple samples reduced this bias. The aneurysm repair score showed a trend of agreement with the assessment using H & E staining, and rosuvastatin also demonstrated robust promotion of EPC proliferation, migration, and tube formation in vitro.

The in vivo dosage of rosuvastatin that we chose was 20 mg/kg/day. We first tested concentrations of rosuvastatin in vitro and found that 100 μmol/L treatment reached the best therapeutic effect with the least unintended effects (Fig. 4). Considering the pharmacokinetics, disposition, and liver-specific distribution of rosuvastatin in vivo, we calculated the concentration, which ranged from 1 to 100 μmol/L. Additionally, the dosages of rosuvastatin previously used in the rat model were 2 mg/kg/day, 5 mg/kg/day, 10 mg/kg/day, and 15 mg/kg/day. The dosage we used in vivo was within the range of previously reported studies. We used a single dosage in our study since the purpose of the study was to supply proof of the principle.

EPCs play an important role during vascular endothelium repair and remodeling, especially in vascular injury.

**Table 2. EPC (monocyte) percentage**

<table>
<thead>
<tr>
<th>Time</th>
<th>Group</th>
<th>AN</th>
<th>AN-Rous</th>
<th>MS</th>
</tr>
</thead>
<tbody>
<tr>
<td>10 days</td>
<td></td>
<td>2.87 ± 0.26†</td>
<td>2.49 ± 0.66</td>
<td>0.88 ± 0.10</td>
</tr>
<tr>
<td>20 days</td>
<td></td>
<td>27 ± 0.32</td>
<td>1.44 ± 0.26</td>
<td>0.86 ± 0.07</td>
</tr>
<tr>
<td>30 days</td>
<td></td>
<td>1.40 ± 0.37</td>
<td>3.56 ± 0.50‡</td>
<td>0.97 ± 0.03</td>
</tr>
</tbody>
</table>

* Values are percentages and represent the mean ± SE (n = 5). Significant differences were assessed using 2-way ANOVA.
† Significantly different from MS group (p < 0.05).
‡ Significantly different from AN group (p < 0.05).
and coiled aneurysms, and EPCs have been found to promote aneurysm neck endothelialization after aneurysm coiling. In this study, we found that the number of circulating EPCs was significantly increased at 10 days after aneurysm coiling—an increase that could have been caused by bone marrow–derived EPC mobilization and homing after vascular injury. During this stage, increased levels of circulating EPCs were primarily ascribed to the vascular injury, but rosuvastatin appeared to produce an observable effect. On the 20th day, most of the circulating EPCs were hypothesized to have migrated to the injured aneurysm neck, targeting the impaired endothelium, thereby decreasing the number of circulating EPCs. Late stages of endothelial repair were present on the 30th day. In this stage, the number of local EPCs decreased, and the number of circulating EPCs recovered to a relatively high level. During this period, the rosuvastatin-treated rats showed significant increases in the number of circulating EPCs. Previous studies showed strong evidence indicating that statins mobilize EPCs from bone marrow to increase the amount of circulating EPCs.

Tissue samples from the coiled aneurysms were assessed after 30 days of rosuvastatin therapy using an aneurysm repair score assessment system that we established. The rosuvastatin-treated rats showed better neurological outcomes than the untreated rats. Regarding the aneurysm repair score and histological examination, rosuvastatin treatment improved aneurysm neck integration and focal endothelialization. Staining for vWF further demonstrated the continuity of the endothelial cell layer in the aneurysm necks obtained from these rats. Similar to the aneurysm repair score, the rosuvastatin-treated rats had additional integrated endothelium compared with the untreated rats with aneurysms. KDR is a representative marker of EPCs, and we found that more KDR+ cells adhered to the impaired aneurysm neck in the rosuvastatin-treated rats, whereas few KDR+ cells were detected in the untreated rats with aneurysms. Our previous study demonstrated the effect of bone marrow–derived EPCs in aneurysm neck endothelialization. In the present study, we further demonstrated that the numbers of circulating EPCs increased in the rosuvastatin-treated rats, and more KDR+ cells adhered to the endothelial layer in the aneurysm neck (Fig. 3), indicating that rosuvastatin could promote EPC attachment to the aneurysm neck. SEM examination demonstrated that the bottom of the aneurysm neck had simple squamous epithelial cells in the rosuvastatin-treated rats (as opposed to spindle endothelial cells). These EPCs were thought to originate from circulating EPCs. Although we found an increase of circulating EPCs in the rosuvastatin-treated animals, we could not show where the increased EPCs came from. As we know, 2 types of endothelial cells were found at the aneurysm neck. One type was squamous endothelial cells, which we found covering the bottom of the aneurysm neck. The other type was the thin and spindle endothelial cells, which surrounded the ring of the aneurysm neck. The latter may come from local neighbor endothelial cells since the cell morphological character was similar to that of the surrounding cells. Nevertheless, rosuvastatin promoted migration of endothelial cells and EPCs toward the aneurysm neck and contributed to its endothelialization.

There are several mechanisms that might have been responsible for the enhanced repair effect induced by the EPCs. First, rosuvastatin accelerated the EPC mobilization from bone marrow and increased the level of circulating EPCs after coiling treatment. Clinical research has shown that long-term statin therapy helps maintain high levels of circulating EPCs. Second, rosuvastatin directly promoted the viability of adherent EPCs and the function of endothelial cells. We found that rosuvastatin positively affected EPC proliferation, migration, and tube formation in rats in vivo, which indicated that the direct promotion of EPCs by rosuvastatin was another crucial component inducing aneurysm neck repair and remodeling. In addition to having a proliferative effect, statins have also been shown to exert positive effects on cell survival and differentiation by reducing apoptosis and suppressing apoptotic cytokines.

Rosuvastatin facilitated local release of endothelium-related cytokines in aneurysm necks, which may promote endothelialization. In addition, the paracrine effect of EPCs may contribute to the acceleration of endothelialization. We intend to further explore the mechanism of action of rosuvastatin in the improvement of aneurysm neck endothelialization in future studies.

Previous studies included somewhat conflicting results. The pathological progress of coiled cerebral aneurysms has been shown to be affected by the interaction of many factors, including EPCs, smooth muscle cells, and inflammation. Although bone marrow–derived EPCs were shown not to be involved in the re-endothelialization of a mouse endothelial denudation model or murine arterial injury model, EPCs were thought to play a key role in the

### Table 3. Optical density value elevation rate after 24-hour treatment with rosuvastatin

<table>
<thead>
<tr>
<th>Concentration (μmol/L)</th>
<th>Change in OD Value (%)†</th>
</tr>
</thead>
<tbody>
<tr>
<td>0.001</td>
<td>107.3 ± 2.3†</td>
</tr>
<tr>
<td>0.010</td>
<td>103.0 ± 1.8</td>
</tr>
<tr>
<td>0.100</td>
<td>101.4 ± 2.2</td>
</tr>
<tr>
<td>1.000</td>
<td>108.0 ± 2.7†</td>
</tr>
<tr>
<td>10.000</td>
<td>108.2 ± 1.7†</td>
</tr>
<tr>
<td>100.000</td>
<td>116.1 ± 2.2†</td>
</tr>
</tbody>
</table>

* OD values are expressed as mean ± SEM (n = 6). Significance was assessed by means of a 1-way ANOVA followed by Dunnett’s t-test. † Significantly different from control group (p < 0.05).

### Table 4. Results of migration and tube formation assays

<table>
<thead>
<tr>
<th>Measure</th>
<th>Rosuvastatin (−)</th>
<th>Rosuvastatin (+)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Fluorescent area of the migration assay</td>
<td>5.4% ± 0.5%</td>
<td>11.8% ± 2.9%†</td>
</tr>
<tr>
<td>Total no. of nets in the tube formation assay</td>
<td>1.0 ± 0</td>
<td>9.3 ± 2.6†</td>
</tr>
</tbody>
</table>

* The values represent the mean ± SE of 5 wells of EPCs for the migration assay and mean ± SE of 3 wells of EPCs for the tube formation assay. † Significantly different from control group (p < 0.05, 1-way ANOVA).
regulation of postinjury vascular endothelialization by secreting cytokines or microvesicles containing DNA, RNA, or microRNA. The beneficial effects of statins in clinical aneurysm treatment are also controversial. A single-center case-control study found no evidence of beneficial effect of statins with respect to intracranial aneurysm suppression. In contrast, the results of a Japanese multicenter case-control study suggested an inverse relationship between statin use and cerebral aneurysm rupture.

Conclusions
The results of our study show that statins had a positive effect of aneurysm repair and indicate that further studies of the role of statins in aneurysm repair should be conducted.

Acknowledgments
This project was sponsored by the National Natural Science Foundation of China, project No. 30973105 (W.Z.); the Program for New Century Excellent Talents in University, project No. XYQ2011019 (W.Z.); and Shanghai Rising Star Program, project No. 13QH1400900 (W.Z.).

References

Unauthenticated | Downloaded 02/18/22 07:32 AM UTC


Disclosure

The authors report no conflict of interest concerning the materials or methods used in this study or the findings specified in this paper.

Author Contributions

Conception and design: Zhu, Chen. Acquisition of data: Chen. Analysis and interpretation of data: Liu, Chen. Drafting the article: Liu. Critically revising the article: An, Huang, Yang. Reviewed submitted version of manuscript: Zhu, An, Huang, Yang. Approved the final version of the manuscript on behalf of all authors: Zhu. Statistical analysis: Liu, An. Administrative/technical/material support: Liu. Study supervision: Yang.

Correspondence

Wei Zhu, Department of Neurosurgery, Huashan Hospital, Fudan University, Wulumuqi Zhong Rd., Shanghai 200040, China. email: drzhuwei@fudan.edu.cn.